PMID- 28571714
OWN - NLM
STAT- MEDLINE
DCOM- 20180509
LR  - 20200306
IS  - 1873-7064 (Electronic)
IS  - 0028-3908 (Print)
IS  - 0028-3908 (Linking)
VI  - 123
DP  - 2017 Sep 1
TI  - L-Tyrosine availability affects basal and stimulated catecholamine indices in 
      prefrontal cortex and striatum of the rat.
PG  - 159-174
LID - S0028-3908(17)30255-1 [pii]
LID - 10.1016/j.neuropharm.2017.05.030 [doi]
AB  - We previously found that L-tyrosine (L-TYR) but not D-TYR administered by reverse 
      dialysis elevated catecholamine synthesis in vivo in medial prefrontal cortex 
      (MPFC) and striatum of the rat (Brodnik et al., 2012). We now report L-TYR 
      effects on extracellular levels of catecholamines and their metabolites. In MPFC, 
      reverse dialysis of L-TYR elevated in vivo levels of dihydroxyphenylacetic acid 
      (DOPAC) (L-TYR 250-1000 muM), homovanillic acid (HVA) (L-TYR 1000 muM) and 
      3-methoxy-4-hydroxyphenylglycol (MHPG) (L-TYR 500-1000 muM). In striatum L-TYR 
      250 muM elevated DOPAC. We also examined L-TYR effects on extracellular dopamine 
      (DA) and norepinephrine (NE) levels during two 30 min pulses (P2 and P1) of K+ 
      (37.5 mM) separated by t = 2.0 h. L-TYR significantly elevated the ratio P2/P1 
      for DA (L-TYR 125 muM) and NE (L-TYR 125-250 muM) in MPFC but lowered P2/P1 for DA 
      (L-TYR 250 muM) in striatum. Finally, we measured DA levels in brain slices using 
      ex-vivo voltammetry. Perfusion with L-TYR (12.5-50 muM) dose-dependently elevated 
      stimulated DA levels in striatum. In all the above studies, D-TYR had no effect. 
      We conclude that acute increases within the physiological range of L-TYR levels 
      can increase catecholamine metabolism and efflux in MPFC and striatum. 
      Chronically, such repeated increases in L-TYR availability could induce adaptive 
      changes in catecholamine transmission while amplifying the metabolic cost of 
      catecholamine synthesis and degradation. This has implications for 
      neuropsychiatric conditions in which neurotoxicity and/or disordered L-TYR 
      transport have been implicated.
CI  - Published by Elsevier Ltd.
FAU - Brodnik, Zachary D
AU  - Brodnik ZD
AD  - Drexel University College of Medicine, Department of Neurobiology and Anatomy, 
      2900 W. Queen Lane, Philadelphia, PA 19129, United States.
FAU - Double, Manda
AU  - Double M
AD  - Medical Research Service, Louis Stokes Cleveland DVAMC, 10701 East Blvd., 
      Cleveland, OH 44106, United States.
FAU - Espana, Rodrigo A
AU  - Espana RA
AD  - Drexel University College of Medicine, Department of Neurobiology and Anatomy, 
      2900 W. Queen Lane, Philadelphia, PA 19129, United States.
FAU - Jaskiw, George E
AU  - Jaskiw GE
AD  - Medical Research Service, Louis Stokes Cleveland DVAMC, 10701 East Blvd., 
      Cleveland, OH 44106, United States; Dept. of Psychiatry, Case Western University 
      Medical Center at W.O. Walker 10524 Euclid Ave, Cleveland, OH 44133, United 
      States. Electronic address: gxj5@case.edu.
LA  - eng
GR  - I01 BX000381/BX/BLRD VA/United States
GR  - R01 DA031900/DA/NIDA NIH HHS/United States
PT  - Journal Article
DEP - 20170529
PL  - England
TA  - Neuropharmacology
JT  - Neuropharmacology
JID - 0236217
RN  - 0 (Catecholamines)
RN  - 0 (Central Nervous System Agents)
RN  - 42HK56048U (Tyrosine)
RN  - RWP5GA015D (Potassium)
SB  - IM
MH  - Animals
MH  - Catecholamines/*metabolism
MH  - Central Nervous System Agents/administration & dosage
MH  - Corpus Striatum/drug effects/*metabolism
MH  - Dose-Response Relationship, Drug
MH  - Extracellular Space/drug effects/metabolism
MH  - Male
MH  - Potassium/metabolism
MH  - Prefrontal Cortex/drug effects/*metabolism
MH  - Rats, Sprague-Dawley
MH  - Synaptic Transmission/drug effects/physiology
MH  - Tissue Culture Techniques
MH  - Tyrosine/administration & dosage/*metabolism
PMC - PMC5544352
MID - NIHMS884751
OTO - NOTNLM
OT  - Dopamine
OT  - Norepinephrine
OT  - Prefrontal cortex
OT  - Striatum
OT  - Tyrosine
OT  - Tyrosine hydroxylase
EDAT- 2017/06/03 06:00
MHDA- 2018/05/10 06:00
PMCR- 2018/09/01
CRDT- 2017/06/03 06:00
PHST- 2017/03/09 00:00 [received]
PHST- 2017/05/22 00:00 [revised]
PHST- 2017/05/26 00:00 [accepted]
PHST- 2017/06/03 06:00 [pubmed]
PHST- 2018/05/10 06:00 [medline]
PHST- 2017/06/03 06:00 [entrez]
PHST- 2018/09/01 00:00 [pmc-release]
AID - S0028-3908(17)30255-1 [pii]
AID - 10.1016/j.neuropharm.2017.05.030 [doi]
PST - ppublish
SO  - Neuropharmacology. 2017 Sep 1;123:159-174. doi: 10.1016/j.neuropharm.2017.05.030. 
      Epub 2017 May 29.